Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) just unveiled an announcement.
Zymeworks Inc., a global biotechnology company, focuses on managing licensed healthcare assets and advancing a pipeline of multifunctional biotherapeutics targeting cancer, inflammatory, and autoimmune diseases, with a business model built around asset and royalty aggregation to support cash flow and innovation. Its flagship HER2-targeted bispecific antibody Ziihera, developed using its proprietary Azymetric platform, along with other candidates such as pasritamig, is being advanced through strategic licensing deals with partners including BeOne Medicines and Jazz Pharmaceuticals.
The company announced it will report first quarter 2026 financial results after the market close on May 7, 2026, followed by a conference call and webcast the same day to review the figures and provide a corporate update. The event, accessible via the investor relations section of Zymeworks’ website, is expected to offer investors and stakeholders additional insight into the performance of its asset- and royalty-driven strategy and the progress of its clinical and commercial pipelines.
The most recent analyst rating on (ZYME) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Overall score reflects a strong earnings-call outlook (clinical validation, regulatory path, improved FY2025 performance, and nondilutive financing) offset by weak underlying financial performance (recent losses and ongoing cash burn) and neutral technicals; valuation remains challenged due to unprofitability (negative P/E).
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global biotechnology company that manages a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics aimed at difficult-to-treat diseases, including cancer, inflammation, and autoimmune conditions. Its strategy centers on asset and royalty aggregation to optimize future cash flows from products such as HER2-targeted bispecific antibody Ziihera (zanidatamab-hrii) and other licensed candidates like pasritamig, supported by proprietary Azymetric technology and partnerships with major biopharmaceutical firms.
The company is also building a broader portfolio of healthcare assets designed to generate strong cash flows while funding the development of innovative antibody-based medicines. Leveraging expertise in antibody drug conjugates and multispecific antibody therapeutics, Zymeworks uses complementary platforms and a fully integrated drug development engine to engineer differentiated therapies and has granted regional development and commercialization rights for zanidatamab to partners including BeOne Medicines and Jazz Pharmaceuticals.
Average Trading Volume: 658,710
Technical Sentiment Signal: Buy
Current Market Cap: $2.06B
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.